AVTE Valuation
Aerovate Therapeutics Inc
$
0.000
- Overview
- Forecast
- Valuation
- Earnings
AVTE Relative Valuation
AVTE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AVTE is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.04
P/B
Median3y
3.15
Median5y
-9.35
-64.24
FCF Yield
Median3y
-42.81
Median5y
-32.77
Competitors Valuation Multiple
The average P/S ratio for AVTE's competitors is 0.71, providing a benchmark for relative valuation. Aerovate Therapeutics Inc Corp (AVTE) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
AIRE
reAlpha Tech Corp
0.419
USD
-7.51%
LINK
Interlink Electronics Inc
6.999
USD
-3.86%
PIII
P3 Health Partners Inc
7.270
USD
-1.76%
AADI
Aadi Bioscience Inc
0
USD
-2.44%
CSLM
CSLM Acquisition Corp
11.690
USD
0.00%
NCSM
NCS Multistage Holdings Inc
30.207
USD
-1.70%
UBCP
United Bancorp Inc
14.405
USD
+2.45%
YYGH
YY Group Holding Ltd
3.390
USD
+11.51%
TPIC
TPI Composites Inc
0.873
USD
-1.91%
ELTK
Eltek Ltd
10.464
USD
+0.62%
FAQ
Is Aerovate Therapeutics Inc (AVTE) currently overvalued or undervalued?
Aerovate Therapeutics Inc (AVTE) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of -7.10. The fair price of Aerovate Therapeutics Inc (AVTE) is between to according to relative valuation methord.
What is Aerovate Therapeutics Inc (AVTE) fair value?
How does AVTE's valuation metrics compare to the industry average?
What is the current P/B ratio for Aerovate Therapeutics Inc (AVTE) as of Jul 27 2025?
What is the current FCF Yield for Aerovate Therapeutics Inc (AVTE) as of Jul 27 2025?
What is the current Forward P/E ratio for Aerovate Therapeutics Inc (AVTE) as of Jul 27 2025?